The clinical predictive ability of five biomarkers (MMP9, Siglec-5, DYSF, MGAM, and S100A12) for the development of BPD was validated, and drug–gene interaction analysis highlighted MGAM and MMP9 as potential therapeutic targets. This evidence concerns the gene MGAM and bronchopulmonary dysplasia.